Frankfurt
11.08.25 | 08:41
0,723 Euro
-2,17 % -0,016
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,768 | 0,829 | 22:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | Saniona AB: Bulletin from the Saniona AB annual shareholders' meeting on May 28, 2025 | 127 | GlobeNewswire (Europe) | Today, on May 28, 2025, the annual shareholders' meeting was held in Saniona AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and distribution of the company's... ► Artikel lesen | |
| 12.05. | Saniona AB: Saniona appoints Johnny Stilou as Chief Financial Officer | 164 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Johnny Stilou as Chief Financial Officer, effective immediately. He brings more than 25 years of... ► Artikel lesen | |
| 10.04. | Saniona - Broad pipeline to address neurological conditions | 376 | Edison Investment Research | Saniona is a European pioneer in ion channel drug discovery. Internally, it is primarily focused on its preclinical epilepsy pipeline: SAN2355 (for focal/generalised epilepsy) and SAN2219 (for acute... ► Artikel lesen | |
| 28.03. | Saniona's CSO to "We are on track with SAN2219" | 2 | Cision News | ||
| 26.03. | Saniona's CEO to "The TO4 proceeds give us flexibility to secure the best deals" | 2 | Cision News | ||
| 26.03. | Saniona AB: Saniona initiates scale-up and manufacturing of toxicology batches for SAN2219, a potential new therapy for epilepsy | 350 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the initiation of scale-up and manufacturing of toxicology batches for SAN2219, advancing the program toward clinical... ► Artikel lesen | |
| 12.03. | Saniona's new CMO to "More deals are definitely on the horizon" | 2 | Cision News | ||
| SANIONA Aktie jetzt für 0€ handeln | |||||
| 11.03. | Saniona AB: Saniona and Boehringer Ingelheim extend research collaboration with one year | 506 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with one year.
"The... ► Artikel lesen | |
| 10.03. | Saniona AB: Saniona Appoints Pierandrea Muglia, M.D., as Chief Medical Officer | 139 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experience... ► Artikel lesen | |
| 07.03. | Saniona's CEO comments on the recent news | 2 | Cision News | ||
| 03.03. | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | 406 | Business Wire | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
| 28.02. | Saniona strengthened its cash position and advanced through partnership | 4 | Cision News | ||
| 27.02. | Saniona AB: Saniona publishes its year-end report for 2024 | 151 | GlobeNewswire (Europe) | Three Months Ended December 31, 2024 (2023)Twelve Months Ended December 31, 2024 (2023)Revenue was SEK 313.4 M (5.4 M)Revenue was SEK 334.7 M (16.8 M)Operating profit/loss was SEK 290.4 M (-19.8 M)Operating... ► Artikel lesen | |
| 24.02. | Saniona's CEO responds to investors' questions | 2 | Cision News | ||
| 28.11.24 | Saniona AB: Saniona publishes its interim report for the third quarter of 2024 | 213 | GlobeNewswire (Europe) | Three Months Ended September 30, 2024 (2023)Nine Months Ended September 30, 2024 (2023)Revenue was SEK 7.2 M (5.5 M)Revenue was SEK 21.3 M (11.5 M)Operating profit/loss was SEK -18.9 M (-18.4 M)Operating... ► Artikel lesen | |
| 14.10.24 | Saniona AB: Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone | 531 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization... ► Artikel lesen | |
| 29.08.24 | Saniona AB: Saniona publishes its interim report for the second quarter of 2024 | 159 | GlobeNewswire (Europe) | Three Months Ended June 30, 2024 (2023)Six Months Ended June 30, 2024 (2023)Revenue was SEK 8.0 M (3.9 M)Revenue was SEK 14.1 M (6.0 M)Operating profit/loss was SEK -16.0 M (-21.8 M)Operating profit/loss... ► Artikel lesen | |
| 29.08.24 | Saniona AB: Saniona publishes its interim report for the second quarter of 2024 | 153 | GlobeNewswire (Europe) | Three Months Ended June 30, 2024 (2023)Six Months Ended June 30, 2024 (2023)Revenue was SEK 8.0 M (3.9 M)Revenue was SEK 14.1 M (6.0 M)Operating profit/loss was SEK -16.0 M (-21.8 M)Operating profit/loss... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,574 | -3,01 % | Aktien Frankfurt Ausblick: Leichte Entspannung nach US-Arbeitsmarktschock | FRANKFURT (dpa-AFX) - Nach einem von Konjunktursorgen getriebenen Rückschlag dürfte sich der deutsche Aktienmarkt am Montag zunächst leicht erholen. Der X-Dax signalisierte für den hiesigen Leitindex... ► Artikel lesen | |
| PAION | 0,010 | 0,00 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| 4SC | 0,552 | +4,15 % | PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025 | DJ PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Planegg-Martinsried (pta000/08.08.2025/07:30... ► Artikel lesen | |
| NANOREPRO | 1,600 | +3,56 % | EQS-DD: NanoRepro AG: Lisa Jüngst, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.08.2025 / 14:00... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,250 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces 1-for-50 Reverse Stock Split | PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its... ► Artikel lesen | |
| BRAIN BIOTECH | 2,070 | -0,48 % | EQS-News: BRAIN Biotech AG: Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Personalie
Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG
23.07.2025 / 08:30 CET/CEST
Für den... ► Artikel lesen | |
| AAP IMPLANTATE | 1,650 | -4,07 % | aap Implantate: Vollständige Zulassung sämtlicher bislang nicht zugelassener Aktien | Bad Marienberg (www.anleihencheck.de) - Die aap Implantate AG (die "Gesellschaft") gibt bekannt, dass sämtliche bislang nicht zugelassenen Aktien der Gesellschaft (bisherige ISIN DE000A32VP65 und DE000A4096G8)... ► Artikel lesen | |
| BIOXXMED | 0,250 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| CLINUVEL | 6,805 | -1,09 % | CLINUVEL PHARMACEUTICALS LIMITED: Bioshares Biotech Summit presentation | ||
| SANGAMO THERAPEUTICS | 0,377 | -3,38 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed... ► Artikel lesen | |
| BIO-GATE | 0,855 | -9,04 % | Bio-Gate mit Verlust, Aktie stürzt ab | Bio-Gate hat die endgültigen Zahlen für 2024 vorgelegt. An der Börse kommen die Zahlen der Bilanz schlecht an: Die Bio-Gate Aktie notiert aktuell bei 0,82 Euro mit 20,39 Prozent im Minus. Das Unternehmen... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,040 | -1,30 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| EDITAS MEDICINE | 1,884 | -0,55 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen |
SANIONA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,17 % bei einem Aktienkurs von 0,723 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANIONA AB finden Sie auf Wallstreet Online.